J&J's lung cancer therapy succeeds in head-to-head study with ... - LCFA
Johnson & Johnson's Rybrevant showed similar effectiveness to AstraZeneca's Tagrisso in treating advanced EGFR mutant NSCLC, with both drugs shrinking or halting tumor growth in about 75% of patients after a year. Rybrevant, approved in 2021 as a second-line treatment, may now also serve as an initial treatment option alongside Tagrisso, offering more effective choices to extend patient lives.
Reference News
Johnson & Johnson's Rybrevant showed similar effectiveness to AstraZeneca's Tagrisso in treating advanced EGFR mutant NSCLC, with both drugs shrinking or halting tumor growth in about 75% of patients after a year. Rybrevant, approved in 2021 as a second-line treatment, may now also serve as an initial treatment option alongside Tagrisso, offering more effective choices to extend patient lives.